Hurel is a biotechnology company focused on replacing or supplementing animal models in drug discovery with its organ-on-a-chip technology. Its lead product recreates functional human liver tissue on a microfluidic chip, allowing researchers to evaluate drug toxicity more accurately than with traditional animal studies. The company also builds multi-tissue microfluidic devices to model complex human biological interactions. By providing earlier and more predictive toxicity data, Hurel aims to shorten development timelines, reduce costs, and improve patient safety. Regulatory interest is growing, as highlighted by FDA commentary on the potential of human-on-a-chip systems. Proceeds from its recent financing will fund the commercial launch of the liver chip and further R&D on next-generation platforms. Hurel has yet to disclose revenue, user numbers, or other operating metrics but has secured $9.2 million in Series A funding to advance its plans.

Total raised

$9M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2013